Fig. 1
From: COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome
Workflow of neoantigens identification from HepG2 HLA-I immunopeptidome. The HepG2 cell HLA-I immunopeptide complex was enriched using the W6/32 antibody. The immunopeptides were then separated from the HLA-I immunopeptide complex using a C18 column and identified through LC-MS/MS analysis. A HepG2 WES-based and COSMIC-based mutation database were utilized to identify potential neoantigens from the immunopeptidomes. Finally, these neoantigen candidates were assessed using bioinformatics tools to confirm their affinity to the HLA-I molecule.